Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)-MedSci.cn

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

Chari, A; Goldschmidt, H; San-Miguel, J; McCarthy, H; Suzuki, K; Hungria, V; Balari, AS; Perrot, A; Hulin, C; Magen, H; Iida, S; Maisnar, V; Karlin, L; Pour, L; Parasrampuria, D; Masterson, T; Kosh, M; Yang, S; Qi, M; Carson, R; Moreau, P

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019; 19 (10): E16

科室
- - 订阅+
  - 更多科室
工具
服务